First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test

Contributed by: Business Wire

Logo

Tags

Oncology

Health

FDA

Medical Devices

Clinical Trials

Research

Science

ASCO investigational exemption screening

More Like This

First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer

Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications

Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types

PR Newswire associated0

A Framework to Evaluate the Clinical Utility of Multicancer Early Detection (MCED) Technologies: Balancing the Utilization of Intermediate and Long-term Data

PR Newswire associated0

Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring

Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

PR Newswire associated0

Invizius's Pioneering Dialysis Product H-Guard® Completes First In-Human Clinical Study